Last edition
News about "AstraZeneca"
AstraZeneca Enters into Global License Agreement with with Dizal Pharmaceutical for Zegfrovy
AstraZeneca has entered a global licensing agreement with Dizal Pharmaceutical for Zegfrovy, expanding its EGFR-targeted lung cancer portfolio.
AstraZeneca | 15/07/2026 | By News Bureau
AstraZeneca, Ionis' Wainua Misses Phase 3 Primary Endpoint in ATTR-CM Trial
AstraZeneca and Ionis reported that Wainua (eplontersen) missed the primary endpoint in the phase 3 CARDIO-TTRansform trial for ATTR-CM, while maintaining a consistent safety profile.
AstraZeneca | 10/07/2026 | By News Bureau
Sino Biopharma and AstraZeneca Sign Licensing Deal for TQC3721
Sino Biopharmaceutical has signed an exclusive licensing agreement with AstraZeneca to develop, manufacture, and commercialise TQC3721, a novel PDE3/4 inhibitor for respiratory diseases.
AstraZeneca | 09/07/2026 | By News Bureau
EMA Recommends Approval of Datroway for First-Line Treatment of Triple-Negative Breast Cancer
AstraZeneca and Daiichi Sankyo have received a positive recommendation from the European Medicines Agency's CHMP for Datroway as a first-line treatment for unresectable or metastatic triple-negative breast cancer in patients who are not eligible for immunotherapy, supported by Phase 3 trial results demonstrating improved survival and disease control.
AstraZeneca | 29/06/2026 | By News Bureau
AstraZeneca's Ultomiris Granted FDA Priority Review for Rare Kidney Disease IgAN
The US FDA has granted Priority Review to AstraZeneca’s supplemental application for Ultomiris in immunoglobulin A nephropathy, bringing the therapy closer to becoming the first C5 complement inhibitor approved for the rare kidney disease.
AstraZeneca | 16/06/2026 | By News Bureau | 106
US Approves TRUQAP for PTEN-Deficient Metastatic Prostate Cancer
TRUQAP (capivasertib) has been approved in the US as the first targeted treatment for PTEN-deficient metastatic Hormone-Sensitive Prostate Cancer (mHSPC). The approval is supported by phase 3 CAPItello-281 data showing a 19 percent reduction in the risk of disease progression or death.
AstraZeneca | 15/06/2026 | By News Bureau
Leica Biosystems, AstraZeneca and Daiichi Sankyo have expanded their strategic collaboration to develop an AI-enabled immunohistochemistry assay and computational pathology solution for evaluating the TROP2 Normalised Membrane Ratio biomarker in NSCLC, aiming to advance biomarker-driven cancer research and future precision medicine approaches.<br />
AstraZeneca | 01/06/2026 | By News Bureau | 136
CARES Phase 3 Trial Highlights Anselamimab Potential in Kappa Light Chain Amyloidosis
Anselamimab demonstrated promising efficacy in the phase 3 CARES programme, showing a 62 percent improvement in survival and a 71 percent reduction in cardiovascular hospitalisations among patients with kappa light-chain amyloidosis, despite the study not meeting its primary endpoint in the overall light-chain amyloidosis population.
AstraZeneca | 01/06/2026 | By News Bureau
IMFINZI from AstraZeneca has received US approval in combination with BCG for BCG-naïve, high-risk non-muscle-invasive bladder cancer, supported by Phase III POTOMAC trial data showing a 32 percent reduction in the risk of disease recurrence, progression, or death after one year of IMFINZI added to BCG vs. BCG alone.
AstraZeneca | 29/05/2026 | By News Bureau
Camizestrant Plus CDK4/6 Inhibitor Recommended for EU Approval in Advanced ER-Positive Breast Cancer
Camizestrant plus a CDK4/6 inhibitor receives CHMP recommendation for EU approval in first-line advanced ER-positive breast cancer, supported by phase 3 SERENA-6 trial results showing a 56 percent reduction in disease progression or death.
AstraZeneca | 25/05/2026 | By News Bureau | 105
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy